Salisbury Foundation Trust

FOI_5276

Internal Reference Number: FOI_5276

Date Request Received: 08/09/2019 07:52:02

Date Request Replied To: 17/10/2019 08:52:35

This response was sent via: By Email

Request Summary: Advanced breast cancer

Request Category: Private Individuals

 
Question Number 1:
Does your trust treat advanced breast cancer ?
 
Answer To Question 1:
Yes
 
Question Number 2:
If none, where are your patients referred?
 
Answer To Question 2:
N/A
 
Question Number 3:
In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;
HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease
Not Known

 
Answer To Question 3:
As agreed with requestor, we are unable to provide a response to this question.
 
Question Number 4:
In the past 3 months, how many breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent
 
Answer To Question 4:
In the past 3 months, how many breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor * 0
Abemaciclib (Verzenios) + Fulvestrant (Faslodex) <5
Alpelisib (Piqray) + Fulvestrant (Faslodex) 0
Atezolizumab (Tecentriq)** 0
Bevacizumab (Avastin) 0
Eribulin (Halaven) 0
Everolimus (Afinitor) + Exemestane <5
Fulvestrant (Faslodex) as a single agent 8
Gemcitabine + paclitaxel 0
Lapatinib (Tyverb) 0
Neratinib (Nerlynx) <5
Olaparib (Lynparza) 0
Palbociclib (Ibrance) + aromatase inhibitor* 15
Pertuzumab (Perjeta) + trastuzumab + docetaxel 8
Ribociclib (Kisqali) + aromatase inhibitor* 0
Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0
Talazoparib (Talzenna) 0
Trastuzumab + paclitaxel 0
Trastuzumab as a single agent 10
Trastuzumab emtansine (Kadcyla) <5
Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole unable to answer within a reasonable timeframe and there are shared care arrangements to this figure would be meaningless
**eg. docetaxel, vinorelbine or capecitabine as a single agent 63

Please note that it is Trust policy not to disclose potentially patient identifiable information, thus if there are less than 5 patients we will specify only '<5'.
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values